Skip to content

    Tarsus Pharmaceuticals (TARS) stock price & financials

    View TARS earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+24.1% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $48.12M
    $66.41M
    $78.33M
    $102.66M
    $118.70M
    +146.7%
    $151.67M
    +128.4%
    $162.05M
    +106.9%
    $173.91M
    +69.4%
    Strengthening
    Operating Profit
    -$25.16M
    -$24.42M
    -$26.28M
    -$22.18M
    -$14.53M
    +42.3%
    -$7.98M
    +67.3%
    -$6.12M
    +76.7%
    -$19.91M
    +10.3%
    Strengthening
    Net Profit
    -$23.42M
    -$23.11M
    -$25.12M
    -$20.34M
    -$12.59M
    +46.3%
    -$8.37M
    +63.8%
    -$6.97M
    +72.3%
    -$18.55M
    +8.8%
    Strengthening
    EPS
    $-0.61
    $-0.64
    $-0.48
    $-0.30
    +50.8%
    $-0.16
    +75.0%
    $-0.43
    +10.4%
    Strengthening
    Other Income
    $1.74M
    $1.31M
    $1.16M
    $1.84M
    $1.94M
    +11.6%
    $1.66M
    +27.1%
    $1.51M
    +29.9%
    $4.07M
    +120.9%
    Strengthening
    Interest
    $2.44M
    $2.31M
    $2.21M
    $2.24M
    $2.27M
    -7.2%
    $2.21M
    -4.2%
    $2.13M
    -3.8%
    $2.16M
    -3.8%
    Weakening
    Depreciation
    Profit before Tax
    MarginsOPM
    -52.3%
    -36.8%
    -33.5%
    -21.6%
    -12.2%
    +76.6%
    -5.3%
    +85.7%
    -3.8%
    +88.7%
    -11.4%
    +47.0%
    Strengthening
    Tax
    ReturnsROIC
    3.4%
    3.3%
    3.6%
    2.9%
    1.8%
    -46.3%
    1.2%
    -63.8%
    1.0%
    -72.3%
    2.7%
    -8.8%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$2.38M$57.95M$168.13M$171.33M$71.66M$224.95M$94.82M$183.64M$204.59M
    Short-Term Investments$0$483.0K$145.37M$2.50M$196.56M$233.63M$245.09M
    Total Current Assets$58.03M$170.66M$175.95M$225.38M$256.13M$356.70M$522.78M$561.99M
    Net PP&E$280.0K$1.24M$1.83M$1.53M$3.35M$2.87M$21.75M$30.40M
    Goodwill
    Intangibles$0$3.87M$8.33M$7.37M$6.88M
    Total Assets$58.32M$171.97M$178.91M$227.86M$265.49M$376.99M$562.16M$611.14M
    LiabilitiesTotal Current Liabilities$819.0K$5.39M$11.48M$15.43M$36.94M$80.61M$135.69M$175.75M
    Short-Term Debt
    Long-Term Debt$0$19.43M$29.82M$71.84M$72.44M$72.76M
    Long-Term Leases$100.0K$549.0K$585.0K$52.0K$1.51M$0$10.60M$15.89M
    Total Liabilities$919.0K$5.99M$12.18M$34.96M$68.50M$152.46M$218.73M$264.41M
    EquityCommon Stock & APIC$2.0K$4.0K$4.0K$5.0K$5.0K$6.0K$6.0K$6.0K
    Retained Earnings-$6.03M-$32.84M-$46.67M-$108.76M-$244.66M-$360.21M-$426.63M-$452.15M
    Total Equity-$1.35M-$6.00M$165.98M$166.73M$192.90M$196.99M$224.53M$343.43M$346.73M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$3.67M-$21.14M$3.75M-$49.03M-$117.49M-$83.03M-$12.45M$74.16M
    Cash from Investing-$175.0K-$456.0K-$586.0K-$144.63M$140.60M-$199.19M-$42.12M$23.85M
    Cash from Financing$59.45M$131.77M$21.0K$93.99M$130.18M$154.66M$143.39M$9.38M
    SummaryCapital Expenditure-$175.0K-$456.0K-$586.0K-$506.0K-$1.50M-$1.57M-$9.86M-$18.16M
    Free Cash Flow-$3.85M-$21.59M$3.16M-$49.54M-$119.00M-$84.59M-$22.31M$56.00M
    FCF Margin5.5%-191.9%-682.0%-46.2%-4.9%9.2%

    Ratios